56 results about "MUC1" patented technology

Provided is an antigen-binding protein targeting MUC1. The antigen-binding protein contains at least one CDR in a heavy chain variable region of an antibody. Further provided are a chimeric antigen receptor, immunoconjugate and pharmaceutical composition containing the antigen-binding protein, a nucleic acid encoding the antigen-binding protein, a vector containing the nucleic acid molecule, a cell containing the vector, and the use of the antigen-binding protein in the prevention and / or treatment of diseases.

MUC1 binding molecules are provided, including MUC1 single domain antibodies that specifically bind to the MUC1 extracellular region. The invention further relates to an anti-MUC1 single-domain antibody chimeric antigen receptor and application thereof, and particularly provides the chimeric antigen receptor, and an antigen binding domain of the chimeric antigen receptor comprises an MUC1 binding molecule containing the anti-MUC1 single-domain antibody. The immune cell containing the chimeric antigen receptor has a relatively high cell killing effect.

This invention relates to an IL5 / Bi2MoO6 / MXene photoactive composite material, a low-background photoelectrochemical aptamer sensor, its preparation method, and its applications. The sensor is constructed by sequentially modifying chitosan, glutaraldehyde, complementary DNA strands, and a gold nanoparticle-labeled aptamer. A fixed capture probe and APT-Au synergistically achieve dual signal quenching, constructing an extremely low detection baseline. When the target analyte MUC1 is present, its specific binding to the aptamer causes APT-Au to detach, dissolving the dual quenching and significantly restoring the photocurrent, thereby achieving quantitative detection. This invention solves the problems of low efficiency, heterojunction instability, and high baseline in single quenching modes of existing photoelectric materials, achieving highly sensitive, highly specific, rapid, and low-cost detection of the breast cancer biomarker MUC1 in human serum samples, providing a novel, industrially feasible technical solution for large-scale early screening of breast cancer.

Provided herein are multiepitope peptides comprising at least one mucin 1 (MUC1) peptide, having MHC affinity for at least one HLA serotype, and recognized by CD4+ T cell receptors and / or CD8+ T cell receptors. Also provided herein are compositions comprising the multiepitope peptides and a cationic lipid, including vaccine compositions. In various embodiments, the cationic lipid is R-DOTAP. The present invention also provides methods of using the multiepitope peptides, as well as compositions and vaccine compositions. These methods of use include methods for treating cancer in a subject and methods for inducing MUC-specific polyfunctional and cytolytic T cell responses in a subject.

A fusion protein comprising: a first component comprising an antibody, or a fragment or variant thereof; and a second component comprising a cytokine trap or an adenosine deaminase or a fragment or variant thereof. In certain embodiments, the antibody is an anti-PD-1 antibody. In certain embodiments, the antibody binds to a tumor antigen, for example a MUC16 or MUC1 antigen. In certain embodiments, the cytokine trap is a TGF-β trap. A polynucleotide encoding such a fusion protein and a vector comprising such a polynucleotide. A composition comprising the fusion protein. A method of using the composition, including in the treatment of cancer.

The present invention is directed to antibodies binding to MUC1-C / extracellular domain (MUC1-C / ECD) and methods of using such antibodies to treat cancers that express the MUC1 antigen.

The present disclosure relates to a novel method of treating squamous cell carcinoma (SCC), and in particular head and neck squamous cell carcinoma (HSSCC) and cutaneous carcinoma (CC) using MUC1-C inhibitors. Also described herein is a novel method of suppressing the progression of premalignant lesions to a squamous cell carcinoma.

The invention belongs to the technical field of medical biological research, and particularly relates to a construction method of a spontaneous emphysema mouse model. The invention relates to a method for constructing a spontaneous emphysema mouse model, which comprises the following steps: when a Muc1 gene whole body knockout mouse naturally senility for 3-18 months to form spontaneous emphysema and / or a Muc1 type 2 alveolar epithelial cell knockout mouse is 6-8 weeks old, injecting tamoxifen into the intraperitoneal cavity of the mouse to induce knockout. According to the invention, the Muc1 gene knockout mouse is used for constructing a spontaneous emphysema mouse model product for the first time; the related products comprise construction schemes, application transformation and the like of a spontaneous emphysema model generated by Muc1 whole body knockout mouse (Muc1- / -) along with age increase and a spontaneous emphysema model generated by Muc1 type 2 alveolar epithelial cell knockout (Muc1AT2- / -) mouse induced by intraperitoneal injection tamoxifen along with age increase. The invention proves that the spontaneous emphysema model is successfully constructed.

Provided are a Surface-Enhanced Raman Scattering (SERS) biosensor based on a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) / Cas13a system and an application thereof, belonging to the field of spectroscopy detection. The SERS biosensor includes an SERS sensor chip, a first reagent, a second reagent, a third reagent, and a fourth reagent. The SERS sensor chip is a silver nanorod array substrate with hairpin Deoxyribonucleic Acid (DNA) single-stranded H1 and blocking molecule 6-mercaptoethanol modified on the surface. The first reagent is a SERS probe and buffer of the probe. The second reagent is hairpin nucleic acid aptamer strand MUC1-apt aqueous solution. The third reagent is the CRISPR / Cas13a system and buffer of the system. The fourth reagent is hairpin DNA single-stranded H2 aqueous solution. The above reagents are mixed with the gastric cancer exosomes to be detected and then dripped on a surface of the SERS sensor chip.

The present disclosure relates to a novel method of treating squamous cell carcinoma (SCC), and in particular head and neck squamous cell carcinoma (HSSCC) and cutaneous carcinoma (CC) using MUC1-C inhibitors. Also described herein is a novel method of suppressing the progression of premalignant lesions to a squamous cell carcinoma.

This invention discloses a composite nanozyme and a kit for simultaneous recognition of multiple exosomes. The kit includes an aptamer / composite nanozyme solution, exosome standards, TMB substrate solution, H2O2 solution, and 96-well plate enzyme labeling strips. This invention innovatively utilizes Ti3C2T... x A nanozyme (MX-MnNF) formed by combining MXene nanosheets and MnO2 nanoflowers was constructed, and a colorimetric sensor array was built by modifying it with three aptamers: EpCAM, MUC1, and HER2. Based on the peroxidase-like activity of the nanozyme, it can catalyze the TMB-H2O2 reaction to produce color changes, enabling the simultaneous recognition of multiple exosomes. This method can complete the detection within 10 minutes, with a detection sensitivity of up to 10 particles / mL and an accuracy of up to 95% for clinical samples. It has the advantages of simple operation, rapid detection, and high sensitivity, providing a new technical means for tumor liquid biopsy.

The application discloses a sequential anti-tumor strategy based on improvement of tumor microenvironment (TME) combined with CAR T and application thereof, and belongs to the technical field of biological medicine, which simultaneously improves tumor fibrosis and acid microenvironment by applying tumor-related fibroblast (CAF) targeting drugs and proton pump inhibitors, and sequentially injects CAR T combined therapy for solid tumors, wherein the CAF targeting drugs are selected from tretinoin, calcipotriol, losartan and minnelide, the proton pump inhibitors are selected from lansoprazole, omeprazole, pantoprazole, rabeprazole and esomeprazole, and the CAR T receptor or ligand is selected from mesothelin, protein tyrosine kinase 7, NKG2D, CD47, B7-H3, MUC1 and HER2; the sequential administration strategy first destroys the dense physical barrier of the tumor microenvironment, improves the acidity of the tumor site, ensures the infiltration, survival and proliferation of CAR T at the tumor site, and then targets and inhibits the growth of solid tumors, especially high-malignancy triple-negative breast cancer, by using the specificity of CAR T.

The present invention relates to: a composition for diagnosing colorectal cancer, comprising a substance capable of measuring the relative expression levels of CCR1, CD177, DLG5, EPCAM, ERBB2, FCGR1A, FOXA2, GK, KRT19, KRT73, MKI67, MPO, MUC1, NME1, NPTN, NQO2, SH2D1B, SNAI2, TERT, TUG1, and VIM genes or proteins encoded by the genes; a kit for diagnosing colorectal cancer, comprising the composition; and a method for diagnosing colorectal cancer by using the kit.

The invention provides a marker, a kit containing the marker, application of the marker and a use method of the marker. The marker comprises at least one selected from the group consisting of MUC1, MUC5AC, and Claudin18.2. The invention also relates to a method for preparing the marker. The marker and the kit containing the marker can be used for predicting prognosis of the intrahepatic cholangiocarcinoma, predicting the curative effect of targeted therapy and postoperative adjuvant therapy on the intrahepatic cholangiocarcinoma based on tumor expression states, and performing classified prediction on a big bile duct type and a small bile duct type of the intrahepatic cholangiocarcinoma. The disclosure also provides a method of cancer prognosis comprising detecting the expression of the marker and predicting the degree of benefit from post-operative adjuvant therapy in a subject, and / or the prognosis of cancer, particularly intrahepatic cholangiocarcinoma, in a subject. The present disclosure provides universal markers that can be used to predict the efficacy of postoperative adjuvant therapy, such as postoperative adjuvant chemotherapy, on intrahepatic cholangiocarcinoma.

The application belongs to the technical field of biotechnology, and discloses a humanized anti-human MUC1 monoclonal antibody and application thereof, the antibody is humanized by CDR grafting technology, three complementarity determining regions of a light chain variable region and three complementarity determining regions of a heavy chain variable region are retained, an amino acid sequence of the light chain variable region is shown in SEQ ID NO. 11, and a corresponding base sequence is shown in SEQ ID NO. 12; an amino acid sequence of the heavy chain variable region is shown in SEQ ID NO. 13, and a corresponding base sequence is shown in SEQ ID NO. 14. The humanized anti-human MUC1 monoclonal antibody can be specifically combined with MUC1 positive tumor cells, and can kill tumor cells through ADCC and CDC effects; can be used for preparing an anti-tumor drug, and the drug forms include a monoclonal antibody, an ADC, a CAR-T cell preparation and BiTEs, and provides an effective targeting tool for immunotherapy of MUC1 overexpression related tumors.

The application provides a multi-specific antibody monomer having a light chain (LC) and a heavy chain (HC), each having a N-terminal and a C-terminal, comprising, a first scFv domain having a binding affinity to a tumor-associated antigen (TAA) at the N-terminal of the HC (Position 1, or P1), a Fab domain having a binding affinity to CD3, and a second scFv domain having a binding affinity to PD-L1 at the C-terminal of the LC (Position 5, or P5) or the N-terminal of the LC (Position 6, or P6). In some embodiments, the TAA comprises EGFR, HER3, DLL3, HER2, GPC3, HLA-G, uPAR, Nectin4, Fra, Tissue Factor, B7-H4, VEGFR2, B7-H3, Muc16, CEACAM6, Claudin6, CLDN18.2, LGR5, GCC, CD20, CD19, Integrin β6, Muc1, CDH6, FAP, CAIX, Integrin β4, CDH17, Lewis B / Y, GPRC5D, CEACAM5, ROR1, or EGFR vIII.

Disclosed herein are methods of decreasing mucus hypersecretion in the lungs comprising administering an effective amount of a MUC1 inhibitor to a subject in need thereof. In certain embodiments, the MUC1 inhibitor is the peptide GO-201, GO-203, or GO-203-2C. In certain embodiments, the subject is a human patient. In certain embodiments, the subject is diagnosed with rhinosinusitis, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, bronchiectasis, asthma, idiopathic pulmonary fibrosis, acute respiratory distress syndrome (ARDS), cystic fibrosis, or a respiratory syncytial virus (RSV) infection.

To provide antibodies that bind to MUC1* receptor effective to treat or prevent MUC1* positive cancer.SOLUTION: Provided is a human or humanized anti-MUC1* antibody or antibody fragment or antibody-like protein that binds to an extracellular domain site of an MUC1 isoform lacking the tandem repeat region or of a decomposed product.SELECTED DRAWING: None

The present disclosure provides multispecific antibodies and antigen binding fragments thereof that bind to human MUC1 and CD16A, pharmaceutical compositions comprising said antibodies and the use of said antibodies or said compositions for the treatment of diseases such as cancer.

The name of the invention is Tn-MUC1 chimeric antigen receptor (CAR) T cell therapy. Various TnMUC1 specific chimeric antigen receptors (CARs), nucleic acids encoding the same, and methods of using the same are provided. Compositions and methods are provided that include a TnMUC1-specific CAR that treats a MUC1-associated cancer in a subject in need thereof.

The invention relates to the field of immunotherapy, in particular to an engineered antigen presenting cell which contains a coding sequence of a multispecific nano antibody. And / or can express and / or secrete a multispecific nano antibody; a tumor-associated antigen is loaded on the carrier, and the tumor-associated antigen is selected from one or more of the following components: P53, Survivin, MUC1, hTERT or KRAS. The antigen presenting cell disclosed by the invention can activate immature T cells and effectively stimulate the effector function of the activated T cells on cancers.

A pharmaceutical composition comprising an antibody-drug conjugate that specifically binds to EGFR and MUC1, and the use thereof in the preparation of a drug used for preventing or treating diseases.

The application discloses a kind of MUC1-CAR-T cells of co-expression BTLA / IL-18R chimeric receptor and preparation method and application thereof, belong to the field of biological medicine technology.The MUC1-CAR-T cell includes BTLA / IL-18R chimeric receptor and MUC1-CAR structure;The present application uses MUC1 as the targeting molecule of CAR-T cell treatment, the extracellular segment of BTLA is connected with the transmembrane region and intracellular section region of IL-18 receptor, and designs co-expression BTLA / IL-18R chimeric receptor.Experiment verifies and finds that BTLA / IL-18R chimeric receptor can significantly improve the tumor killing ability of MUC1-CAR-T cell, can better inhibit the growth of tumor, provides a new immunotherapy strategy for the treatment of pancreatic cancer.

The invention relates to polypeptide of a targeted tumor marker MUC1 and application of the polypeptide, and belongs to the technical field of nano medicine and biological materials. The sequence general formula of the polypeptide from the N terminal to the C terminal is X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13, x1, X2 and X3 are hydrophilic amino acids, X4-X12 are combinations of leucine, glutamine, isoleucine, threonine and lysine, and X13 is a hydrophobic amino acid. The polypeptide not only can be combined with a target spot with high affinity, but also can be self-assembled into a zigzag nanoflower, so that recognition residues of the polypeptide are functionally arranged on the surface of the nanoflower. The serrated polypeptide nanoflower can be used as a therapeutic drug in the aspect of tumor treatment, and can also be used as a delivery carrier.

The application provides an antigen epitope polypeptide and a paralichthys ovatus mucin Muc1 specific antibody prepared by the antigen epitope, a B cell epitope from the paralichthys ovatus Muc1 protein is identified through antigen epitope screening, and the amino acid sequence is SEQ ID NO:1. After the epitope is coupled with a KLH carrier protein, a New Zealand white rabbit is immunized, and a rabbit anti-paralichthys ovatus Muc1 polyclonal antibody is successfully prepared. The antibody can specifically recognize the Muc1 protein in paralichthys ovatus mucosa tissue and positive mucous cells, and provides an important detection tool for studying the function mechanism of mucous cells in fish mucosal immunity.

MUC1 is overexpressed in many cancers, including those of the lung, colon, breast, ovary, and pancreas. Aspects of the invention are directed towards the discovery of monoclonal antibodies and fragments thereof, such as a human single chain variable fragment (scFv), that recognizes human MUC1-SEA.

To provide an antibody for diagnosis, treatment, or prevention of cancer.SOLUTION: There is provided an antibody or a fragment thereof for diagnosis, treatment, or prevention of cancer, the antibody specifically binding to a PSMGFR peptide (SEQ ID NO: 2) or a fragment of the peptide.SELECTED DRAWING: None

The invention relates to the technical field of biological detection, and discloses a saliva exosome detection kit for non-invasive auxiliary screening of Alzheimer's disease and a preparation method of the saliva exosome detection kit. The specific exosome enrichment system composed of the anti-L1CAM / CD63 double antibody coated capture plate and the anti-MUC1 / KRT19Fab fragment blocking agent is constructed for the first time, about 85% of oral cavity source exosomes can be effectively removed, and the capture purity of neuron source exosomes is remarkably improved; the special saliva preserving fluid containing DTT and a specific enzyme inhibitor is developed, the technical bottlenecks that saliva RNA is easy to degrade and a sample is uneven in viscosity are overcome, and the room temperature stability is prolonged to 8 hours; an RT-qPCR detection system taking saliva exosome miRNA-135a as a core and taking internal reference miRNA-16-5p standardization is established, and clinical sample verification shows that the kit can effectively distinguish the Alzheimer's disease patient from a healthy control, shows excellent inter-group distinguishing ability, and provides a stable, efficient, reliable and complete technical scheme for solving the problem of AD non-invasive early screening.

The invention provides a probe for detecting CTC (circulating tumor cell) by a bispecific electrochemical sensor system and a detection method, and belongs to the technical field of biological detection. The detection system provided by the invention comprises an EpCAM / MUC1 aptamer bispecific coupling magnetic bead CTC capture probe and an EpCAM / MUC1 aptamer bispecific coupling nano-enzyme CTC signal probe. According to the detection method, the capture efficiency is improved by utilizing the synergistic effect of the two aptamers. According to the detection method, the peripheral blood circulating tumor cells can be rapidly detected under the condition that the sample size is small. The detection method is good in accuracy and high in sensitivity, and can provide accurate detection results for disease diagnosis.

The present invention is in the fields of diagnostics and treatment of cancer. The present invention provides, inter alia, means and methods for detecting and / or isolating metastasis founder cells based on the expression or expression level of the marker(s) c-KIT and / or MUC1, and, preferably, at least one additional disseminated cancer cell (DCC) marker such as EpCAM and / or (a) cytokeratin(s). Corresponding isolated cells or cell populations, and uses thereof, are provided as well. In one aspect, the invention relates to a method for detecting metastasis founder cells in a sample, comprising measuring in single cells in a sample the expression or expression level of (i) a first marker which is c-KIT and (ii) at least one disseminated cancer cell (DCC) marker, wherein expression of c-KIT and at least one DCC marker in a cell is indicative of the cell being a metastasis founder cell, or wherein expression levels of c-KIT and at least one DCC marker in a cell above respective thresholds are indicative of the cell being a metastasis founder cell. Furthermore, the invention relates to methods for prognosing the development of metastases and / or the relapse, progression or outcome of a cancer, as well as to methods for measuring the success of an anti-cancer treatment and / or for stratifying subjects for treatment with (an) anti-cancer drug(s), based on the expression or expression level of said marker(s) in single cells. In addition, the present invention relates to one or more anti-cancer drugs for use in treating a patient having metastasis founder cells according to the invention. Further provided are therapeutics for targeting metastasis founder cells such as antibodies or fragments thereof binding both, c-KIT and EpCAM, or CAR-T cells targeting both, c-KIT and EpCAM.